<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We and others recently reported <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> ligand-related leukocyte-expressed ligand 1 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TALL</z:e>-1) as a novel member of the TNF ligand family that is functionally involved in B cell proliferation </plain></SENT>
<SENT sid="1" pm="."><plain>Transgenic mice overexpressing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TALL</z:e>-1 have severe B cell <z:mpath ids='MPATH_134'>hyperplasia</z:mpath> and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e>-like <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we describe expression cloning of a cell surface receptor for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TALL</z:e>-1 from a human Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> RAJI cell library </plain></SENT>
<SENT sid="3" pm="."><plain>The cloned receptor is identical to the previously reported TNF receptor (TNFR) homologue transmembrane activator and calcium modulator and cyclophilin ligand (CAML) interactor (TACI) </plain></SENT>
<SENT sid="4" pm="."><plain>Murine TACI was subsequently isolated from the mouse B <z:hpo ids='HP_0002665'>lymphoma</z:hpo> A20 cells </plain></SENT>
<SENT sid="5" pm="."><plain>Human and murine TACI share 54% identity overall </plain></SENT>
<SENT sid="6" pm="."><plain>Human TACI exhibits high binding affinities to both human and murine <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TALL</z:e>-1 </plain></SENT>
<SENT sid="7" pm="."><plain>Soluble TACI extracellular domain protein specifically blocks <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TALL</z:e>-1-mediated B cell proliferation without affecting CD40- or <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi>-mediated B cell proliferation in vitro </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, when injected into mice, soluble TACI inhibits antibody production to both T cell-dependent and -independent antigens </plain></SENT>
<SENT sid="9" pm="."><plain>By yeast two-hybrid screening of a B cell library with TACI intracellular domain, we identified that, like many other TNFR family members, TACI intracellular domain interacts with TNFR-associated factor (TRAF)2, 5, and 6 </plain></SENT>
<SENT sid="10" pm="."><plain>Correspondingly, TACI activation in a B cell line results in nuclear factor kappaB and c-Jun NH(2)-terminal kinase activation </plain></SENT>
<SENT sid="11" pm="."><plain>The identification and characterization of the receptor for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TALL</z:e>-1 provides useful information for the development of a treatment for B cell-mediated <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> such as <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> </plain></SENT>
</text></document>